Polymun Our company was founded in 1992. It is a private company fully owned. Revenues are generated by contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. The company operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. The last inspection has taken place in September 2008. The core competence of our company is the development and manufacture of biopharmaceuticals, using both mammalian mammalian and microbial cell technology. A fine example are our broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, we can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.